The surface composition of asteroid 162173 Ryugu from Hayabusa2 near-infrared spectroscopy

The near-Earth asteroid 162173 Ryugu, the target of the Hayabusa2 sample-return mission, is thought to be a primitive carbonaceous object. We report reflectance spectra of Ryugu's surface acquired with the Near-Infrared Spectrometer (NIRS3) on Hayabusa2, to provide direct measurements of the surface composition and geological context for the returned samples. A weak, narrow absorption feature centered at 2.72 micrometers was detected across the entire observed surface, indicating that hydroxyl (OH)-bearing minerals are ubiquitous there. The intensity of the OH feature and low albedo are similar to thermally and/or shock-metamorphosed carbonaceous chondrite meteorites. There are few variations in the OH-band position, which is consistent with Ryugu being a compositionally homogeneous rubble-pile object generated from impact fragments of an undifferentiated aqueously altered parent body.

The geomorphology, color, and thermal properties of Ryugu: Implications for parent-body processes

The near-Earth carbonaceous asteroid 162173 Ryugu is thought to have been produced from a parent body that contained water ice and organic molecules. The Hayabusa2 spacecraft has obtained global multicolor images of Ryugu. Geomorphological features present include a circum-equatorial ridge, east-west dichotomy, high boulder abundances across the entire surface, and impact craters. Age estimates from the craters indicate a resurfacing age of [Formula: see text] years for the top 1-meter layer. Ryugu is among the darkest known bodies in the Solar System. The high abundance and spectral properties of boulders are consistent with moderately dehydrated materials, analogous to thermally metamorphosed meteorites found on Earth. The general uniformity in color across Ryugu's surface supports partial dehydration due to internal heating of the asteroid's parent body.

Frequency and risk factors of thoracic metastases and optimisation of the use of cross-sectional chest imaging in follow-up patients with cervical cancer

AIM

To optimise cross-sectional chest imaging usage by identifying frequency and risk factors associated with thoracic metastases in cervical cancer patients after initial definitive treatment.

MATERIALS AND METHODS

This study, conducted during 2004-2015, examined 361 consecutive patients with histopathologically proven cervical carcinoma with at least 1 year of follow-up. Electronic medical records and all available imaging modes were used to record and assess patient and tumour characteristics and timing of thoracic metastases. Associations with these characteristics and thoracic metastases were assessed using univariate and multivariable Cox proportional hazards modelling.

RESULTS

Of the 361 patients, 31 developed thoracic metastases. Multivariate regression results showed that adeno/adenosquamous carcinomas (hazard ratio [HR], 2.46; 95% confidence interval [CI], 1.06 to 5.72), other histology (HR, 5.61; 95% CI, 1.81 to 17.42), high International Federation of Gynaecology and Obstetrics (FIGO) stage (HR, 2.84; 95% CI, 1.09 to 7.37), and presence of initial intra-abdominal lymph node metastases (HR, 2.46; 95% CI, 1.02 to 5.90) were associated significantly and independently with thoracic metastases. The second analysis among the subgroup of surgical treatment identified intermediate-high risk classification of recurrence (HR, 5.12; 95% CI, 1.14 to 22.94), high FIGO stage (HR, 2.73; 95% CI, 1.05 to 7.13), and other histology (HR, 11.51; 95% CI, 3.66 to 36.19) as independent predictors of thoracic metastases. Two of the 361 and 2/313 patients with thoracic metastases who did not correspond to the conditions above were in the respective evaluation groups.

CONCLUSION

Assessment of negative prognostic factors for thoracic metastases might contribute to reduced need for chest cross-sectional chest computed tomography examinations.

Abstract P5-03-08: Eribulin-induced EpCAM expression provides drug resistance in triple-negative breast cancer cells

Breast cancer is the most common cancer in women in the world. Among breast cancer subtypes, triple-negative breast cancer is aggressive. Because there is no effective therapy for triple-negative breast cancer, development of a novel therapeutic strategy is required.

Eribulin, a derivative of halicondrin B, is an anticancer chemical. Eribulin treatment has been approved in many countries for patients with metastatic or inoperable breast cancer, including triple-negative breast cancer. The known functions of Eribulin are inhibition of microtubule polymerization and induction of the expression of epithelial genes in breast cancer cells. However, the function of Eribulin-induced genes on the therapy for patients with triple-negative breast cancer remains unclear.

EpCAM (Epithelial cell adhesion molecule) is one of epithelial markers and known as a cell-cell adhesion molecule. In addition, EpCAM expression is involved in drug resistance in cancer. We therefore focused on EpCAM expression in Eribulin-treated breast cancer cells.

We used MDA-MB-231 cells that is a commonly used triple-negative breast cancer cell line. We treated cells with 10 nM Eribulin and observed inhibition of cell growth. In the same condition, we found up-regulation of EpCAM expression in both mRNA and protein levels. In mouse xenograft model with MDA-MB-231 cells, EpCAM expression was detected in whole tumor at 96 h after Eribulin administration. We analyzed the effect of other microtubule polymerization inhibitors, nocodazole and colchicine, on EpCAM induction. In the results, there was no up-regulation of EpCAM expression in cells treated with these chemicals, suggesting that EpCAM expression is not induced by inhibition of microtubule polymerization and growth inhibition.

To analyze EpCAM function on Eribulin treatment, we constructed shRNA-mediated EpCAM knockdown system. We introduced EpCAM knockdown in MDA-MB-231 cells and treated with Eribulin. In the results of cell growth assays, the cell number of Eribulin-treated EpCAM-knockdown cells was significantly smaller than that of Eribulin-treated control-shRNA cells, whereas no change was observed between solvent-treated control-shRNA and EpCAM-knockdown groups. In mouse xenograft experiments, EpCAM-knockdown cells showed smaller tumor weights than control-shRNA cells after administration of Eribulin. These results indicate that EpCAM expression provides Eribulin resistance in breast cancer cells.

In conclusion, we found Eribulin-induced EpCAM expression in triple-negative breast cancer cells. The EpCAM expression provides Eribulin resistance both in vitro and in vivo. These suggest that a combination of Eribulin treatment and EpCAM inhibition may improve therapy for breast cancer.

Citation Format: Tanaka S, Itou J, Sato F, Toi M. Eribulin-induced EpCAM expression provides drug resistance in triple-negative breast cancer cells [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-03-08.

Abstract P2-01-11: A peptide with the conserved amino acid residue of integrin α6 inhibits metastasis through disruption of complex formation in breast cancer cells

Metastasis inhibition may improve survival of breast cancer patients. Our previous study revealed that a transcription factor SALL4 promotes cell migration for metastasis through up-regulation of integrin α6β1 in metastatic basal-like breast cancer cells. In these cells, integrin α6β1 modulates Rho GTPase activity, which enhances focal adhesion dynamics for cell migration. We therefore focused on integrin α6 as a therapeutic target for metastasis.

We investigated the expression level of integrin α6 in breast cancer cell lines and a tissue microarray of breast cancer patients. In both experiments, we observed higher integrin α6 expression in basal-like breast cancer cells than in luminal ones. We performed shRNA-mediated integrin α6 knockdown in basal-like breast cancer cells and conducted Boyden chamber assays. In the results, reduced cell migration was observed in integrin α6 knocked-down cells. Reciprocally, we introduced integrin α6 overexpression in low-migratory luminal breast cancer cell lines and observed increased cell migration. These results indicate that integrin α6 promotes cell migration in breast cancer cells.

To identify the functional residue of integrin α6, we analyzed its amino acid sequence by in silico analyses. First, we extracted integrin α6 specific residues in integrin α family in the human genome. Then, we compared integrin α6 sequences among vertebrates. In the result, we obtained an integrin α6-specific and vertebrate-conserved sequence, Asp-358, as a candidate for the functional residue.

To inhibit integrin α6 function, we designed an 8-amino acid peptide with the sequence around Asp-358. Basal-like breast cancer cells treated with the peptide showed reduced cell migration in a dose-dependent manner. The peptide did not reduce cell migration in integrin α6 knocked-down cells, suggesting that the peptide inhibits integrin α6 function. To determine whether the peptide inhibits metastasis, we performed zebrafish metastasis assays, and observed reduced metastasis rate in the peptide-treated group. These results indicate that the peptide inhibits metastasis through reduction in cell migration.

To understand the effect of the peptide, we performed chemical cross-liking assay in a basal-like breast cancer cell line. Protein samples from the cells treated with a cross-linker showed bands of integrin α6 complexes, and the intensities of these bands were reduced in the peptide-treated group. Moreover, we immunostained cells with an antibody for focal adhesion marker, phospho-paxillin, because integrins regulates focal adhesion formation for cell migration. In the results, the peptide reduced the number of focal adhesions. These observations indicate that the peptide inhibits integrin α6 function. In the future, our findings may contribute to development of a metastasis inhibition therapy.

Citation Format: Itou J, Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Sato F, Toi M. A peptide with the conserved amino acid residue of integrin α6 inhibits metastasis through disruption of complex formation in breast cancer cells [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-01-11.

Denis RD, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark GH, Stark J, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teischinger FA, Teixeira-Dias P, Temming KK, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Tupputi SA, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Valderanis C, Valdes Santurio E, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Graaf H, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vasquez GA, Vazeille F, Vazquez Schroeder T, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vishwakarma A, Vittori C, Vivarelli I, Vlachos S, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang Q, Wang R, Wang SM, Wang T, Wang W, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Weber SA, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Wetter J, Whalen K, Whallon NL, Wharton AM, White A, White MJ, White R, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wobisch M, Wolf TMH, Wolff R, Wolter MW, Wolters H, Worm SD, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xu D, Xu L, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yuen SPY, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zeng JC, Zeng Q, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang R, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou M, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, zur Nedden M, Zwalinski L. Erratum to: Measurement of the W boson polarisation in t t ¯ events from pp collisions at s = 8 TeV in the lepton + jets channel with ATLAS

[This corrects the article DOI: 10.1140/epjc/s10052-017-4819-4.].

Search for electroweak production of supersymmetric particles in final states with two or three leptons at s = 13 TeV with the ATLAS detector

A search for the electroweak production of charginos, neutralinos and sleptons decaying into final states involving two or three electrons or muons is presented. The analysis is based on 36.1 fb- 1 ofs = 13  TeV proton-proton collisions recorded by the ATLAS detector at the Large Hadron Collider. Several scenarios based on simplified models are considered. These include the associated production of the next-to-lightest neutralino and the lightest chargino, followed by their decays into final states with leptons and the lightest neutralino via either sleptons or Standard Model gauge bosons; direct production of chargino pairs, which in turn decay into leptons and the lightest neutralino via intermediate sleptons; and slepton pair production, where each slepton decays directly into the lightest neutralino and a lepton. No significant deviations from the Standard Model expectation are observed and stringent limits at 95% confidence level are placed on the masses of relevant supersymmetric particles in each of these scenarios. For a massless lightest neutralino, masses up to 580 GeV are excluded for the associated production of the next-to-lightest neutralino and the lightest chargino, assuming gauge-boson mediated decays, whereas for slepton-pair production masses up to 500 GeV are excluded assuming three generations of mass-degenerate sleptons.

Network meta-analysis of the relative efficacy of bariatric surgeries for diabetes remission

BACKGROUND

Bariatric surgery leads to a higher remission rate for type 2 diabetes mellitus than non-surgical treatment. However, it remains unsolved which surgical procedure is the most efficacious. This network meta-analysis aimed to rank surgical procedures in terms of diabetes remission.

METHODS AND FINDINGS

We electronically searched for randomized controlled trials in which at least one surgical treatment was included among multiple arms and the diabetes remission rate was included in study outcomes. A random-effects network meta-analysis was performed within a frequentist framework. The hierarchy of treatments was expressed as the surface under the cumulative ranking curve value. Results of the analysis of 25 eligible randomized controlled trials that covered non-surgical treatments and eight surgical procedures (biliopancreatic diversion [BPD], BPD with duodenal switch, Roux-en Y gastric bypass, mini gastric bypass [mini-GBP], laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, greater curvature plication and duodenal-jejunal bypass) showed that BPD and mini-GBP had the highest surface under the cumulative ranking curve values among the eight surgical treatments.

CONCLUSION

Current network meta-analysis indicated that BPD or mini-GBP achieved higher diabetes remission rates than the other procedures. However, the result needs to be interpreted with caution considering that these procedures were in the minority of bariatric surgeries.

Concentrations and biological half-life of radioactive cesium in epigeic earthworms after the Fukushima Dai-ichi Nuclear Power Plant accident

To understand the long-term behavior of radiocesium in the biological processes of a forest ecosystem, its concentration in Japanese epigeic earthworms (Megascolecidae), litter, and soil, and the ambient dose equivalent rates, were investigated after the Fukushima Dai-ichi Nuclear Power Plant accident. The metabolism of radiocesium in the earthworms was also investigated in the laboratory, and its biological half-life (T_b) was estimated. The concentration of ¹³⁷Cs in the habitat soil and litter changed from 2014 to 2016, with levels in the litter going from 44.9 Bq/g dw (in 2014) to 45.3 Bq/g dw (2015) and 10.7 Bq/g dw (2016); in soil, these values were 9.79 Bq/g dw, 7.14 Bq/g dw and 18.0 Bq/g dw, respectively. By contrast, no significant changes were observed in the concentrations in the earthworms, which were 4.87 Bq/g fw, 5.30 Bq/g fw and 4.67 Bq/g fw in 2014, 2015, and 2016, respectively. The ambient dose equivalent rates at the sampling site declined significantly over these three years, going from 2.15 μSv/h to 1.68 μSv/h and 1.35 μSv/h, mostly corresponding to physical decay of radiocesium. The majority (95%) of the ¹³⁷Cs in the earthworms, observed via autoradiography, was concentrated primarily in the intestine. The clearance of ¹³⁷Cs from the earthworms was described by dual exponential functions: the half-life in the rapid loss due to gut clearance was 0.10 days and a second slower loss due to physiological clearance was 27.4 days.

Panagiotopoulou E, Panagoulias I, Pandini CE, Panduro Vazquez JG, Pani P, Panitkin S, Pantea D, Paolozzi L, Papadopoulou TD, Papageorgiou K, Paramonov A, Paredes Hernandez D, Parker AJ, Parker KA, Parker MA, Parodi F, Parsons JA, Parzefall U, Pascuzzi VR, Pasner JMP, Pasqualucci E, Passaggio S, Pastore F, Pataraia S, Pater JR, Pauly T, Pearson B, Pedraza Lopez S, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penwell J, Peralva BS, Perego MM, Perepelitsa DV, Peri F, Perini L, Pernegger H, Perrella S, Peschke R, Peshekhonov VD, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrolo E, Petrov M, Petrucci F, Pettersson NE, Peyaud A, Pezoa R, Phillips FH, Phillips PW, Piacquadio G, Pianori E, Picazio A, Piccaro E, Pickering MA, Piegaia R, Pilcher JE, Pilkington AD, Pin AWJ, Pinamonti M, Pinfold JL, Pirumov H, Pitt M, Plazak L, Pleier MA, Pleskot V, Plotnikova E, Pluth D, Podberezko P, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Pommès K, Ponomarenko D, Pontecorvo L, Popeneciu GA, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pozo Astigarraga ME, Pralavorio P, Pranko A, Prell S, Price D, Primavera M, Prince S, Proklova N, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Puri A, Puzo P, Qian J, Qin G, Qin Y, Quadt A, Queitsch-Maitland M, Quilty D, Raddum S, Radeka V, Radescu V, Radhakrishnan SK, Radloff P, Rados P, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Rangel-Smith C, Rashid T, Raspopov S, Ratti MG, Rauch DM, Rauscher F, Rave S, Ravinovich I, Rawling JH, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reed RG, Reeves K, Rehnisch L, Reichert J, Reiss A, Rembser C, Ren H, Rescigno M, Resconi S, Resseguie ED, Rettie S, Reynolds E, Rezanova OL, Reznicek P, Rezvani R, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel CJ, Rieger J, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ripellino G, Ristić B, Ritsch E, Riu I, Rizatdinova F, Rizvi E, Rizzi C, Roberts RT, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robson A, Rocco E, Roda C, Rodina Y, Rodriguez Bosca S, Rodriguez Perez A, Rodriguez Rodriguez D, Roe S, Rogan CS, Røhne O, Roloff J, Romaniouk A, Romano M, Romano Saez SM, Romero Adam E, Rompotis N, Ronzani M, Roos L, Rosati S, Rosbach K, Rose P, Rosien NA, Rossi E, Rossi LP, Rosten JHN, Rosten R, Rotaru M, Rothberg J, Rousseau D, Rozanov A, Rozen Y, Ruan X, Rubbo F, Rühr F, Ruiz-Martinez A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Ruthmann N, Ryabov YF, Rybar M, Rybkin G, Ryu S, Ryzhov A, Rzehorz GF, Saavedra AF, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Saha P, Sahinsoy M, Saimpert M, Saito M, Saito T, Sakamoto H, Sakurai Y, Salamanna G, Salazar Loyola JE, Salek D, Sales De Bruin PH, Salihagic D, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Martinez V, Sanchez Pineda A, Sandaker H, Sandbach RL, Sander CO, Sandhoff M, Sandoval C, Sankey DPC, Sannino M, Sano Y, Sansoni A, Santoni C, Santos H, Santoyo Castillo I, Sapronov A, Saraiva JG, Sarrazin B, Sasaki O, Sato K, Sauvan E, Savage G, Savard P, Savic N, Sawyer C, Sawyer L, Saxon J, Sbarra C, Sbrizzi A, Scanlon T, Scannicchio DA, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer L, Schaefer R, Schaeffer J, Schaepe S, Schaetzel S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schegelsky VA, Scheirich D, Schernau M, Schiavi C, Schier S, Schildgen LK, Schillo C, Schioppa M, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schnoor U, Schoeffel L, Schoening A, Schoenrock BD, Schopf E, Schott M, Schouwenberg JFP, Schovancova J, Schramm S, Schuh N, Schulte A, Schultens MJ, Schultz-Coulon HC, Schulz H, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schweiger H, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scornajenghi M, Scuri F, Scutti F, Searcy J, Seema P, Seidel SC, Seiden A, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Semprini-Cesari N, Senkin S, Serfon C, Serin L, Serkin L, Sessa M, Seuster R, Severini H, Sforza F, Sfyrla A, Shabalina E, Shaikh NW, Shan LY, Shang R, Shank JT, Shapiro M, Shatalov PB, Shaw K, Shaw SM, Shcherbakova A, Shehu CY, Shen Y, Sherafati N, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimojima M, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shmeleva A, Shoaleh Saadi D, Shochet MJ, Shojaii S, Shope DR, Shrestha S, Shulga E, Shupe MA, Sicho P, Sickles AM, Sidebo PE, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Silva J, Silverstein SB, Simak V, Simic L, Simion S, Simioni E, Simmons B, Simon M, Sinervo P, Sinev NB, Sioli M, Siragusa G, Siral I, Sivoklokov SY, Sjölin J, Skinner MB, Skubic P, Slater M, Slavicek T, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smiesko J, Smirnov N, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith JW, Smith MNK, Smith RW, Smizanska M, Smolek K, Snesarev AA, Snyder IM, Snyder S, Sobie R, Socher F, Soffer A, Søgaard A, Soh DA, Sokhrannyi G, Solans Sanchez CA, Solar M, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Sopczak A, Sosa D, Sotiropoulou CL, Soualah R, Soukharev AM, South D, Sowden BC, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spettel F, Spieker TM, Spighi R, Spigo G, Spiller LA, Spousta M, Denis RDS, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanitzki MM, Stapf B, Stapnes S, Starchenko EA, Stark GH, Stark J, Stark SH, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultan DMS, Sultansoy S, Sumida T, Sun S, Sun X, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Tahirovic E, Taiblum N, Takai H, Takashima R, Takasugi EH, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor AJ, Taylor GN, Taylor PTE, Taylor W, Teixeira-Dias P, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thiele F, Thomas JP, Thomas-Wilsker J, Thompson AS, Thompson PD, Thomsen LA, Thomson E, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorova-Nova S, Todt S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Treado CJ, Trefzger T, Tresoldi F, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tsang KW, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Tupputi SA, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Vadla KOH, Vaidya A, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Valéry L, Valkar S, Vallier A, Valls Ferrer JA, Van Den Wollenberg W, Van der Graaf H, Van Gemmeren P, Van Nieuwkoop J, Van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez GA, Vasquez JG, Vazeille F, Vazquez Schroeder T, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen AT, Vermeulen JC, Vetterli MC, Viaux Maira N, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vishwakarma A, Vittori C, Vivarelli I, Vlachos S, Vogel M, Vokac P, Volpi G, von der Schmitt H, Von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Šfiligoj T, Vuillermet R, Vukotic I, Ženiš T, Živković L, Wagner P, Wagner W, Wagner-Kuhr J, Wahlberg H, Wahrmund S, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang Q, Wang R, Wang SM, Wang T, Wang W, Wang WX, Wang Z, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb AF, Webb S, Weber MS, Weber SA, Weber SW, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weirich M, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Weston TD, Whalen K, Whallon NL, Wharton AM, White AS, White A, White MJ, White R, Whiteson D, Whitmore BW, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winkels E, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wobisch M, Wolf TMH, Wolff R, Wolter MW, Wolters H, Wong VWS, Worm SD, Wosiek BK, Wotschack J, Woźniak KW, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xia L, Xu D, Xu L, Xu T, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamane F, Yamatani M, Yamazaki Y, Yan Z, Yang HJ, Yang HT, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yigitbasi E, Yildirim E, Yorita K, Yoshihara K, Young CJS, Young C, Yu J, Yu J, Yuen SPY, Yusuff I, Zabinski B, Zacharis G, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanzi D, Zeitnitz C, Zemaityte G, Zemla A, Zeng JC, Zeng Q, Zenin O, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang P, Zhang R, Zhang R, Zhang X, Zhang Y, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhou B, Zhou C, Zhou L, Zhou MS, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Zobernig G, Zoccoli A, Zou R, Zur Nedden M, Zwalinski L. Performance of missing transverse momentum reconstruction with the ATLAS detector using proton-proton collisions at s = 13 TeV

The performance of the missing transverse momentum ( E T miss ) reconstruction with the ATLAS detector is evaluated using data collected in proton-proton collisions at the LHC at a centre-of-mass energy of 13 TeV in 2015. To reconstruct E T miss , fully calibrated electrons, muons, photons, hadronically decaying τ -leptons , and jets reconstructed from calorimeter energy deposits and charged-particle tracks are used. These are combined with the soft hadronic activity measured by reconstructed charged-particle tracks not associated with the hard objects. Possible double counting of contributions from reconstructed charged-particle tracks from the inner detector, energy deposits in the calorimeter, and reconstructed muons from the muon spectrometer is avoided by applying a signal ambiguity resolution procedure which rejects already used signals when combining the various E T miss contributions. The individual terms as well as the overall reconstructed E T miss are evaluated with various performance metrics for scale (linearity), resolution, and sensitivity to the data-taking conditions. The method developed to determine the systematic uncertainties of the E T miss scale and resolution is discussed. Results are shown based on the full 2015 data sample corresponding to an integrated luminosity of 3.2 fb - 1 .

Do sarcopenia and/or osteoporosis increase the risk of frailty? A 4-year observation of the second and third ROAD study surveys

In this 4-year follow-up study including 1083 subjects (≥ 60 years), the prevalence of frailty was estimated to be 5.6%; osteoporosis was found to be significantly associated with frailty. Moreover, the presence of both osteoporosis and sarcopenia increased the risk of frailty compared to the presence of osteoporosis or sarcopenia alone.

INTRODUCTION

This study aims to examine the contribution of sarcopenia and osteoporosis to the occurrence of frailty using 4-year follow-up information of a population-based cohort study.

METHODS

The second survey of the Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study was conducted between 2008 and 2010; 1083 subjects (aged ≥ 60 years, 372 men, 711 women) completed all examinations on frailty, sarcopenia, and osteoporosis, which were defined using Fried's definition, Asian Working Group for Sarcopenia criteria, and WHO criteria, respectively. The third survey was conducted between 2012 and 2013; 749 of 1083 individuals enrolled from the second survey (69.2%, 248 men, 501 women) completed assessments identical to those in the second survey.

RESULTS

The prevalence of frailty in the second survey was 5.6% (men, 3.8%; women, 6.6%). The cumulative incidence of frailty was 1.2%/year (men, 0.8%/year; women, 1.3%/year). After adjustment for confounding factors, logistic regression analysis indicated that osteoporosis was significantly associated with the occurrence of frailty (odds ratio, 3.07; 95% confidence interval, 1.26-7.36; p = 0.012). Moreover, the occurrence of frailty significantly increased according to the presence of osteoporosis and sarcopenia (odds ratio vs. neither osteoporosis nor sarcopenia: osteoporosis alone, 2.50; osteoporosis and sarcopenia, 5.80).

CONCLUSIONS

Preventing osteoporosis and coexistence of osteoporosis and sarcopenia may help reduce the risk of frailty.

Vegetative growth after flowering through gibberellin biosynthesis regulates pod setting rate in soybean (Glycine max (L.) Merr.)

Pod setting rate in soybean is an important trait that determines pod number, which is highly correlated with seed yield. Using two soybean cultivars with different pod setting rates, we examined the relationship between plant growth regulation by gibberellin (GA) and pod setting rate. Plant growth rate (PGR) after flowering was significantly higher in 'Fukuyutaka' (low pod setting rate) than in 'Kariyutaka' (high pod setting rate); this difference was caused by increasing of GA biosynthesis-related genes expression. Additionally, pod setting rate in 'Fukuyutaka' was lower than that in 'Kariyutaka'. Furthermore, when 'Kariyutaka' was treated with GA after flowering, the PGR increased and pod setting rate decreased. These results suggest that pod setting rate in soybean is regulated by vegetative growth after flowering through GA biosynthesis.

Muscle layer thickness affects the peroral endoscopic myotomy procedure complexity

Esophageal motility disorders can cause severe dysphagia, regurgitation, and/or noncardiac chest pain due to a lack of coordinated esophageal motility function. However, the clinical significance of esophageal muscle layer thickness remains unclear. The aims of this study are to elucidate the clinical significance of esophageal muscle layer thickness in patients with esophageal motility disorders who undergo peroral endoscopic myotomy (POEM), and to identify predictors of a longer POEM procedure time. Seventy-four consecutive patients with esophageal motility disorders who underwent POEM procedures at Kobe University Hospital from April 2015 to December 2016 were prospectively recruited into this study. First, we investigated the associations between the thickness of the esophageal muscular layer and clinical parameters. There were no significant differences, except in the POEM procedure time, between the patients with esophageal muscle layer thickness values of ≥1.5 mm (group A) and <1.5 mm (group B). However, the relative frequency of a longer POEM procedure time (≥78 min) was significantly higher in group A than in group B (66.7% vs. 19.5, P < 0.0001). Next, independent clinical factors that were related to longer POEM procedures were investigated. Multivariate logistic regression analysis with stepwise selection demonstrated that a thick esophageal muscle layer and the length of myotomy were an independent predictor of a longer POEM procedure (odds ratio: 13.9 and 12.0, respectively). Our results indicate that preoperative endoscopic ultrasonography evaluations can help to predict the technical complexity of POEM procedures.

Prognostic usefulness of arm circumference and nutritional screening tools in older patients with cardiovascular disease

BACKGROUND AND AIM

Arm circumference (AC) and nutritional screening tools have been shown to have prognostic capability in patients with cardiovascular disease (CVD). This study aimed to compare the prognostic predictive capabilities of AC and nutritional screening tools in older patients with CVD.

METHODS AND RESULTS

The study population consisted of 949 admitted patients ≥60 years old with CVD. Patients underwent AC measurement and nutritional screening before hospital discharge. We used the controlling nutritional status index (CONUT), the geriatric nutritional risk index (GNRI), and the prognostic nutritional index (PNI) as nutritional screening tools. The end point of the study was all-cause mortality. The mean age of the study population was 72.3 ± 7.2 years, and 68.2% of the patients were male. A total of 130 deaths occurred over a median follow-up period of 2.2 years (interquartile range, 1.1-3.8 years). After adjusting for other prognostic factors, AC (hazard ratio [HR]: 0.59; p < 0.001), CONUT (HR: 0.82; p = 0.016), GNRI (HR: 0.77; p = 0.040), and PNI (HR: 0.80; p = 0.014) were significant predictors of mortality. However, adding AC to the multivariate-adjusted model (0.739 vs. 0.714, respectively; p = 0.037), but not CONUT, GNRI, or PNI (0.724, 0.717, and 0.723 vs. 0.714; p = 0.072, p = 0.306, and p = 0.127, respectively), significantly increased the area under the curve on receiver operating characteristic curve.

CONCLUSIONS

AC, but not nutritional screening tools, plays a complementary role to preexisting prognostic factors for predicting prognosis in older patients with CVD.

Diagnosis of superficial esophageal squamous cell carcinoma invasion depth before endoscopic submucosal dissection

Endoscopic submucosal dissection (ESD) is a widely accepted procedure for superficial esophageal squamous cell carcinoma (SESCC) limited to the epithelium or lamina propria mucosae (EP/LPM). We aimed to compare the efficacy of endoscopic ultrasonography (EUS) and magnifying endoscopy with narrow band imaging (ME-NBI) for predicting the tumor invasion depth in patients with SESCC. Specifically, we evaluated the ability of these examinations to distinguish EP/LPM from SESCC invading the muscularis mucosae or superficial submucosa (MM/SM1) and more deeply invasive lesions before ESD.We retrospectively analyzed a database of all patients with SESCC who had undergone both EUS and ME-NBI for pretreatment staging and ESD resection at Hiroshima University Hospital between September 2007 and June 2015. The clinicopathologic characteristics of SESCCs were classified according to the Japanese Classification of Esophageal Cancer.A total of 174 lesions in 174 patients were included: 124 (71%) EP/LPMs, 35 (20%) MM/SM1s, and 15 (9%) SESCCs invading the mid submucosae (SM2). The sensitivity of EUS and of ME-NBI in distinguishing EP/LPM from MM/SM1 and more invasive lesions was 72% and 83%, respectively. The accuracy of EUS and ME-NBI in distinguishing EP/LPM from MM/SM1 and more invasive lesions was 70% and 82%, respectively. Sensitivity and accuracy of ME-NBI in distinguishing EP/LPM from MM/SM1 and more deeply invasive SESCCs is significantly higher than those of EUS (P = 0.048 and P = 0.017, respectively).ME-NBI may be more useful than EUS for the determination of SESCC invasion depth before ESD.

Panagiotopoulou E, Panagoulias I, Pandini CE, Panduro Vazquez JG, Pani P, Panitkin S, Pantea D, Paolozzi L, Papadopoulou TD, Papageorgiou K, Paramonov A, Paredes Hernandez D, Parker AJ, Parker MA, Parker KA, Parodi F, Parsons JA, Parzefall U, Pascuzzi VR, Pasner JM, Pasqualucci E, Passaggio S, Pastore F, Pataraia S, Pater JR, Pauly T, Pearson B, Pedraza Lopez S, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penwell J, Peralva BS, Perego MM, Perepelitsa DV, Peri F, Perini L, Pernegger H, Perrella S, Peschke R, Peshekhonov VD, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrolo E, Petrov M, Petrucci F, Pettersson NE, Peyaud A, Pezoa R, Phillips FH, Phillips PW, Piacquadio G, Pianori E, Picazio A, Pickering MA, Piegaia R, Pilcher JE, Pilkington AD, Pinamonti M, Pinfold JL, Pirumov H, Pitt M, Plazak L, Pleier MA, Pleskot V, Plotnikova E, Pluth D, Podberezko P, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Pommès K, Ponomarenko D, Pontecorvo L, Popeneciu GA, Portillo Quintero DM, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pozo Astigarraga ME, Pralavorio P, Pranko A, Prell S, Price D, Primavera M, Prince S, Proklova N, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Puri A, Puzo P, Qian J, Qin G, Qin Y, Quadt A, Queitsch-Maitland M, Quilty D, Raddum S, Radeka V, Radescu V, Radhakrishnan SK, Radloff P, Rados P, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Rangel-Smith C, Rashid T, Raspopov S, Ratti MG, Rauch DM, Rauscher F, Rave S, Ravinovich I, Rawling JH, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reed RG, Reeves K, Rehnisch L, Reichert J, Reiss A, Rembser C, Ren H, Rescigno M, Resconi S, Resseguie ED, Rettie S, Reynolds E, Rezanova OL, Reznicek P, Rezvani R, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel CJ, Rieger J, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ripellino G, Ristić B, Ritsch E, Riu I, Rizatdinova F, Rizvi E, Rizzi C, Roberts RT, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robson A, Rocco E, Roda C, Rodina Y, Rodriguez Bosca S, Rodriguez Perez A, Rodriguez Rodriguez D, Roe S, Rogan CS, Røhne O, Roloff J, Romaniouk A, Romano M, Romano Saez SM, Romero Adam E, Rompotis N, Ronzani M, Roos L, Rosati S, Rosbach K, Rose P, Rosien NA, Rossi E, Rossi LP, Rosten JHN, Rosten R, Rotaru M, Rothberg J, Rousseau D, Roy D, Rozanov A, Rozen Y, Ruan X, Rubbo F, Rühr F, Ruiz-Martinez A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Ruthmann N, Rüttinger EM, Ryabov YF, Rybar M, Rybkin G, Ryu S, Ryzhov A, Rzehorz GF, Saavedra AF, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Saha P, Sahinsoy M, Saimpert M, Saito M, Saito T, Sakamoto H, Sakurai Y, Salamanna G, Salazar Loyola JE, Salek D, Sales De Bruin PH, Salihagic D, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Martinez V, Sanchez Pineda A, Sandaker H, Sandbach RL, Sander CO, Sandhoff M, Sandoval C, Sankey DPC, Sannino M, Sano Y, Sansoni A, Santoni C, Santos H, Santoyo Castillo I, Sapronov A, Saraiva JG, Sarrazin B, Sasaki O, Sato K, Sauvan E, Savage G, Savard P, Savic N, Sawyer C, Sawyer L, Saxon J, Sbarra C, Sbrizzi A, Scanlon T, Scannicchio DA, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer L, Schaefer R, Schaeffer J, Schaepe S, Schaetzel S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Schiavi C, Schier S, Schildgen LK, Schillo C, Schioppa M, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schnoor U, Schoeffel L, Schoening A, Schoenrock BD, Schopf E, Schott M, Schouwenberg JFP, Schovancova J, Schramm S, Schuh N, Schulte A, Schultens MJ, Schultz-Coulon HC, Schulz H, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schweiger H, Schwemling P, Schwienhorst R, Schwindling J, Sciandra A, Sciolla G, Scornajenghi M, Scuri F, Scutti F, Searcy J, Seema P, Seidel SC, Seiden A, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Semprini-Cesari N, Senkin S, Serfon C, Serin L, Serkin L, Sessa M, Seuster R, Severini H, Šfiligoj T, Sforza F, Sfyrla A, Shabalina E, Shaikh NW, Shan LY, Shang R, Shank JT, Shapiro M, Shatalov PB, Shaw K, Shaw SM, Shcherbakova A, Shehu CY, Shen Y, Sherafati N, Sherman AD, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimojima M, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shmeleva A, Shoaleh Saadi D, Shochet MJ, Shojaii S, Shope DR, Shrestha S, Shulga E, Shupe MA, Sicho P, Sickles AM, Sidebo PE, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Silva J, Silverstein SB, Simak V, Simic L, Simion S, Simioni E, Simmons B, Simon M, Sinervo P, Sinev NB, Sioli M, Siragusa G, Siral I, Sivoklokov SY, Sjölin J, Skinner MB, Skubic P, Slater M, Slavicek T, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smiesko J, Smirnov N, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith JW, Smith MNK, Smith RW, Smizanska M, Smolek K, Snesarev AA, Snyder IM, Snyder S, Sobie R, Socher F, Soffer A, Søgaard A, Soh DA, Sokhrannyi G, Solans Sanchez CA, Solar M, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Sopczak A, Sosa D, Sotiropoulou CL, Sottocornola S, Soualah R, Soukharev AM, South D, Sowden BC, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spettel F, Spieker TM, Spighi R, Spigo G, Spiller LA, Spousta M, St. Denis RD, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanitzki MM, Stapf BS, Stapnes S, Starchenko EA, Stark GH, Stark J, Stark SH, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stegler M, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultan DMS, Sultansoy S, Sumida T, Sun S, Sun X, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Tahirovic E, Taiblum N, Takai H, Takashima R, Takasugi EH, Takeda K, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor AJ, Taylor GN, Taylor PTE, Taylor W, Teixeira-Dias P, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Thais SJ, Theveneaux-Pelzer T, Thiele F, Thomas JP, Thomas-Wilsker J, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Tian Y, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorova-Nova S, Todt S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Treado CJ, Trefzger T, Tresoldi F, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tsang KW, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Uno K, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Vadla KOH, Vaidya A, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Valéry L, Valkar S, Vallier A, Valls Ferrer JA, Van Den Wollenberg W, van der Graaf H, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vasquez GA, Vazeille F, Vazquez Furelos D, Vazquez Schroeder T, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen AT, Vermeulen JC, Vetterli MC, Viaux Maira N, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vishwakarma A, Vittori C, Vivarelli I, Vlachos S, Vogel M, Vokac P, Volpi G, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wagner-Kuhr J, Wahlberg H, Wahrmund S, Wakamiya K, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang Q, Wang RJ, Wang R, Wang SM, Wang T, Wang W, Wang W, Wang Z, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb AF, Webb S, Weber MS, Weber SM, Weber SW, Weber SA, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weirich M, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Weston TD, Whalen K, Whallon NL, Wharton AM, White AS, White A, White MJ, White R, Whiteson D, Whitmore BW, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winkels E, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wobisch M, Wolf A, Wolf TMH, Wolff R, Wolter MW, Wolters H, Wong VWS, Woods NL, Worm SD, Wosiek BK, Wotschack J, Wozniak KW, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xia L, Xu D, Xu L, Xu T, Xu W, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamane F, Yamatani M, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yigitbasi E, Yildirim E, Yorita K, Yoshihara K, Young C, Young CJS, Yu J, Yu J, Yuen SPY, Yusuff I, Zabinski B, Zacharis G, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanzi D, Zeitnitz C, Zemaityte G, Zemla A, Zeng JC, Zeng Q, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang P, Zhang R, Zhang R, Zhang X, Zhang Y, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhou B, Zhou C, Zhou L, Zhou M, Zhou M, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, Zou R, zur Nedden M, Zwalinski L. Measurement of the inclusive and fiducial t t ¯ production cross-sections in the lepton+jets channel in pp collisions at s = 8 TeV with the ATLAS detector

The inclusive and fiducial t t ¯ production cross-sections are measured in the lepton+jets channel using 20.2 fb - 1 of proton-proton collision data at a centre-of-mass energy of 8 TeV recorded with the ATLAS detector at the LHC. Major systematic uncertainties due to the modelling of the jet energy scale and b-tagging efficiency are constrained by separating selected events into three disjoint regions. In order to reduce systematic uncertainties in the most important background, the W +\,jets process is modelled using Z + jets events in a data-driven approach. The inclusive t t ¯ cross-section is measured with a precision of 5.7% to beσ inc ( t t ¯ ) = 248.3 ± 0.7 ( stat . ) ± 13.4 ( syst . ) ± 4.7 ( lumi . ) pb , assuming a top-quark mass of 172.5 GeV. The result is in agreement with the Standard Model prediction. The cross-section is also measured in a phase space close to that of the selected data. The fiducial cross-section isσ fid ( t t ¯ ) = 48.8 ± 0.1 ( stat . ) ± 2.0 ( syst . ) ± 0.9 ( lumi . ) pb with a precision of 4.5%.

Curative Criteria After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinomas

BACKGROUND

According to the Japanese Esophageal Society (JES) guidelines, risk factors for lymph node (LN) metastasis in the muscularis mucosa (MM)/submucosa to a depth of up to 200 μm (SM1) in cases of esophageal squamous cell carcinomas (ESCCs) include the presence of lymphatic invasion (ly), venous invasion (v), infiltration pattern (INF)c, and SM1. The long-term prognoses of these patients are unclear, and there are very few reports on the validation of the curative criteria for MM/SM1 ESCCs.

AIMS

To examine the long-term prognoses of these patients and the risk factors for LN metastasis of MM/SM1 ESCCs after endoscopic resection (ER).

METHODS

This study included patients with MM/SM1 ESCCs who underwent ER at Hiroshima University Hospital from December 1990 to November 2016. We evaluated the clinicopathological characteristics of 98 patients and overall survival, disease-specific survival, recurrence-free survival, and recurrence rates in the e-curative and non-e-curative groups.

RESULTS

The mean observation period was 75 months. There was no significant difference in disease-specific survival rate between the e-curative and non-e-curative groups (100 vs. 98%). There was no significant difference in disease-specific survival rates between the groups (100 vs. 98%). In contrast, the LN recurrence-free survival rate in patients with INFa, ly(-), and v(-) was significantly higher than that in patients with INFb/c, ly(+), or v(+) (100 and 87%, P < 0.05).

CONCLUSION

Contrary to the JES guidelines, our findings suggest that new criteria (MM/SM1, INFa, negative vertical margin (VM0), ly[-], and v[-]) may be associated with curative ER without additional treatment.

Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis

OBJECTIVE

The role of baseline severity as effect modifier in various psychiatric disorders is a topic of controversy and of clinical import. This study aims to examine whether baseline severity modifies the efficacy of various antidepressants for major depression through individual participant data (IPD) meta-analysis.

METHOD

We identified all placebo-controlled, double-blind randomised trials of new generation antidepressants in the acute phase treatment of major depression conducted in Japan and requested their IPD through the public-private partnerships (PPPs) between the relevant academic societies and the pharmaceutical companies. The effect modification by baseline depression severity was examined through six increasingly complex competing mixed-effects models for repeated measures.

RESULTS

We identified eleven eligible trials and obtained IPD from six, which compared duloxetine, escitalopram, mirtazapine, paroxetine or bupropion against placebo (total n = 2464). The best-fitting model revealed that the interaction between baseline severity and treatment was not statistically significant (coefficient = -0.04, 95% confidence interval: -0.16 to 0.08, P = 0.49). Several sensitivity analyses confirmed the robustness of the findings.

CONCLUSION

We may expect as much benefit from antidepressant treatments for mild, moderate or severe major depression. Clinical practice guidelines will need to take these findings into consideration.

Panagiotopoulou E, Panagoulias I, Pandini CE, Panduro Vazquez JG, Pani P, Panitkin S, Pantea D, Paolozzi L, Papadopoulou TD, Papageorgiou K, Paramonov A, Paredes Hernandez D, Parker AJ, Parker MA, Parker KA, Parodi F, Parsons JA, Parzefall U, Pascuzzi VR, Pasner JM, Pasqualucci E, Passaggio S, Pastore F, Pataraia S, Pater JR, Pauly T, Pearson B, Pedraza Lopez S, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penwell J, Peralva BS, Perego MM, Perepelitsa DV, Peri F, Perini L, Pernegger H, Perrella S, Peschke R, Peshekhonov VD, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrolo E, Petrov M, Petrucci F, Pettersson NE, Peyaud A, Pezoa R, Phillips FH, Phillips PW, Piacquadio G, Pianori E, Picazio A, Piccaro E, Pickering MA, Piegaia R, Pilcher JE, Pilkington AD, Pin AWJ, Pinamonti M, Pinfold JL, Pirumov H, Pitt M, Plazak L, Pleier MA, Pleskot V, Plotnikova E, Pluth D, Podberezko P, Poettgen R, Poggi R, Poggioli L, Pohl D, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Pommès K, Ponomarenko D, Pontecorvo L, Popeneciu GA, Poppleton A, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Poulard G, Poulsen T, Poveda J, Pozo Astigarraga ME, Pralavorio P, Pranko A, Prell S, Price D, Primavera M, Prince S, Proklova N, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Puri A, Puzo P, Qian J, Qin G, Qin Y, Quadt A, Queitsch-Maitland M, Quilty D, Raddum S, Radeka V, Radescu V, Radhakrishnan SK, Radloff P, Rados P, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Rangel-Smith C, Rashid T, Raspopov S, Ratti MG, Rauch DM, Rauscher F, Rave S, Ravinovich I, Rawling JH, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reed RG, Reeves K, Rehnisch L, Reichert J, Reiss A, Rembser C, Ren H, Rescigno M, Resconi S, Resseguie ED, Rettie S, Reynolds E, Rezanova OL, Reznicek P, Rezvani R, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel CJ, Rieger J, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ripellino G, Ristić B, Ritsch E, Riu I, Rizatdinova F, Rizvi E, Rizzi C, Roberts RT, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robson A, Rocco E, Roda C, Rodina Y, Rodriguez Bosca S, Rodriguez Perez A, Rodriguez Rodriguez D, Roe S, Rogan CS, Røhne O, Roloff J, Romaniouk A, Romano M, Romano Saez SM, Romero Adam E, Rompotis N, Ronzani M, Roos L, Rosati S, Rosbach K, Rose P, Rosien NA, Rossi E, Rossi LP, Rosten JHN, Rosten R, Rotaru M, Rothberg J, Rousseau D, Rozanov A, Rozen Y, Ruan X, Rubbo F, Rühr F, Ruiz-Martinez A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Ruthmann N, Ryabov YF, Rybar M, Rybkin G, Ryu S, Ryzhov A, Rzehorz GF, Saavedra AF, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Saha P, Sahinsoy M, Saimpert M, Saito M, Saito T, Sakamoto H, Sakurai Y, Salamanna G, Salazar Loyola JE, Salek D, Sales De Bruin PH, Salihagic D, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Martinez V, Sanchez Pineda A, Sandaker H, Sandbach RL, Sander CO, Sandhoff M, Sandoval C, Sankey DPC, Sannino M, Sano Y, Sansoni A, Santoni C, Santos H, Santoyo Castillo I, Sapronov A, Saraiva JG, Sarrazin B, Sasaki O, Sato K, Sauvan E, Savage G, Savard P, Savic N, Sawyer C, Sawyer L, Saxon J, Sbarra C, Sbrizzi A, Scanlon T, Scannicchio DA, Scarcella M, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer L, Schaefer R, Schaeffer J, Schaepe S, Schaetzel S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schegelsky VA, Scheirich D, Schernau M, Schiavi C, Schier S, Schildgen LK, Schillo C, Schioppa M, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schnoor U, Schoeffel L, Schoening A, Schoenrock BD, Schopf E, Schott M, Schouwenberg JFP, Schovancova J, Schramm S, Schuh N, Schulte A, Schultens MJ, Schultz-Coulon HC, Schulz H, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schweiger H, Schwemling P, Schwienhorst R, Schwindling J, Sciandra A, Sciolla G, Scornajenghi M, Scuri F, Scutti F, Searcy J, Seema P, Seidel SC, Seiden A, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Semprini-Cesari N, Senkin S, Serfon C, Serin L, Serkin L, Sessa M, Seuster R, Severini H, Sfiligoj T, Sforza F, Sfyrla A, Shabalina E, Shaikh NW, Shan LY, Shang R, Shank JT, Shapiro M, Shatalov PB, Shaw K, Shaw SM, Shcherbakova A, Shehu CY, Shen Y, Sherafati N, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimojima M, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shmeleva A, Shoaleh Saadi D, Shochet MJ, Shojaii S, Shope DR, Shrestha S, Shulga E, Shupe MA, Sicho P, Sickles AM, Sidebo PE, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Silva J, Silverstein SB, Simak V, Simic L, Simion S, Simioni E, Simmons B, Simon M, Sinervo P, Sinev NB, Sioli M, Siragusa G, Siral I, Sivoklokov SY, Sjölin J, Skinner MB, Skubic P, Slater M, Slavicek T, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smiesko J, Smirnov N, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith JW, Smith MNK, Smith RW, Smizanska M, Smolek K, Snesarev AA, Snyder IM, Snyder S, Sobie R, Socher F, Soffer A, Søgaard A, Soh DA, Sokhrannyi G, Solans Sanchez CA, Solar M, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Sopczak A, Sosa D, Sotiropoulou CL, Soualah R, Soukharev AM, South D, Sowden BC, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spettel F, Spieker TM, Spighi R, Spigo G, Spiller LA, Spousta M, St. Denis RD, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanitzki MM, Stapf BS, Stapnes S, Starchenko EA, Stark GH, Stark J, Stark SH, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultan DMS, Sultansoy S, Sumida T, Sun S, Sun X, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takasugi EH, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teixeira-Dias P, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thiele F, Thomas JP, Thomas-Wilsker J, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorova-Nova S, Todt S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Treado CJ, Trefzger T, Tresoldi F, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tsang KW, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Tupputi SA, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Vadla KOH, Vaidya A, Valderanis C, Valdes Santurio E, Valentinetti S, Valero A, Valéry L, Valkar S, Vallier A, Valls Ferrer JA, Van Den Wollenberg W, van der Graaf H, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vasquez GA, Vazeille F, Vazquez Schroeder T, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen AT, Vermeulen JC, Vetterli MC, Viaux Maira N, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vishwakarma A, Vittori C, Vivarelli I, Vlachos S, Vogel M, Vokac P, Volpi G, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wagner-Kuhr J, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang Q, Wang R, Wang SM, Wang T, Wang W, Wang W, Wang Z, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb AF, Webb S, Weber MS, Weber SW, Weber SA, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weirich M, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Whalen K, Whallon NL, Wharton AM, White AS, White A, White MJ, White R, Whiteson D, Whitmore BW, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winkels E, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wobisch M, Wolf TMH, Wolff R, Wolter MW, Wolters H, Wong VWS, Worm SD, Wosiek BK, Wotschack J, Wozniak KW, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xia L, Xu D, Xu L, Xu T, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamatani M, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yigitbasi E, Yildirim E, Yorita K, Yoshihara K, Young C, Young CJS, Yu J, Yu J, Yuen SPY, Yusuff I, Zabinski B, Zacharis G, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanzi D, Zeitnitz C, Zemaityte G, Zemla A, Zeng JC, Zeng Q, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang P, Zhang R, Zhang R, Zhang X, Zhang Y, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhou B, Zhou C, Zhou L, Zhou M, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, Zou R, zur Nedden M, Zwalinski L. Search for a new heavy gauge-boson resonance decaying into a lepton and missing transverse momentum in 36 fb - 1 of pp collisions at s = 13 TeV with the ATLAS experiment

The results of a search for new heavy W ' bosons decaying to an electron or muon and a neutrino using proton-proton collision data at a centre-of-mass energy ofs = 13  TeV are presented. The dataset was collected in 2015 and 2016 by the ATLAS experiment at the Large Hadron Collider and corresponds to an integrated luminosity of 36.1 fb - 1 . As no excess of events above the Standard Model prediction is observed, the results are used to set upper limits on the W ' boson cross-section times branching ratio to an electron or muon and a neutrino as a function of the W ' mass. Assuming a W ' boson with the same couplings as the Standard Model W boson, W ' masses below 5.1 TeV are excluded at the 95% confidence level.

Search for heavy ZZ resonances in the ℓ + ℓ - ℓ + ℓ - and ℓ + ℓ - ν ν ¯ final states using proton-proton collisions at s = 13 TeV with the ATLAS detector

A search for heavy resonances decaying into a pair of Z bosons leading toℓ + ℓ - ℓ + ℓ - andℓ + ℓ - ν ν ¯ final states, where ℓ stands for either an electron or a muon, is presented. The search uses proton-proton collision data at a centre-of-mass energy of 13  TeV corresponding to an integrated luminosity of 36.1  fb - 1 collected with the ATLAS detector during 2015 and 2016 at the Large Hadron Collider. Different mass ranges for the hypothetical resonances are considered, depending on the final state and model. The different ranges span between 200 and 2000  GeV . The results are interpreted as upper limits on the production cross section of a spin-0 or spin-2 resonance. The upper limits for the spin-0 resonance are translated to exclusion contours in the context of Type-I and Type-II two-Higgs-doublet models, while those for the spin-2 resonance are used to constrain the Randall-Sundrum model with an extra dimension giving rise to spin-2 graviton excitations.